Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Baxter
Express Scripts
McKesson
Johnson and Johnson

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,772,325


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,772,325 protect, and when does it expire?

Patent 8,772,325 protects VIBERZI and is included in one NDA.

This patent has eighty-two patent family members in thirty-four countries.

Summary for Patent: 8,772,325
Title:Compounds as opioid receptor modulators
Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Inventor(s): Breslin; Henry J. (Lansdale, PA), Cai; Chaozhong (North Wales, PA), He; Wei (Audubon, PA), Kavash; Robert W. (Glenside, PA)
Assignee: Janssen Pharmaceutica, N.V. (Beerse, BE)
Application Number:14/045,008
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,772,325
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,772,325

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No   Start Trial   Start Trial TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).   Start Trial
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes   Start Trial   Start Trial TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,772,325

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048269   Start Trial
Argentina 095848   Start Trial
Austria 516274   Start Trial
Australia 2005224091   Start Trial
Brazil PI0508820   Start Trial
Canada 2560047   Start Trial
China 102786476   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
Express Scripts
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.